Results 181 to 190 of about 99,677 (264)

Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists. [PDF]

Oncologist
Hoang T, Khan S, Sacher A.
europepmc   +1 more source

Difficult‐to‐Treat Rheumatoid Arthritis With Concomitant Yao Syndrome With Response to Dual‐Inhibitor Therapy

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Nawar Aljundi, Paramarajan Piranavan
wiley   +1 more source

Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in BRAF‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report

Cancer Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background The BRAF V600E mutation is a rare genetic alteration in cholangiocarcinoma for which sequential therapy with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors may be effective. However, the full spectrum of adverse events associated with the sequential use of these agents remains unclear. Hemophagocytic lymphohistiocytosis
Akira Shibata, Michihiro Ono, Shutaro Oiwa, Atsushi Uesugi, Seiya Saito, Makoto Usami, Tomoyuki Abe, Masahiro Yoshida, Masahiro Maeda, Kohichi Takada   +9 more
wiley   +1 more source

Non‐Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature

Annals of the Child Neurology Society, Volume 4, Issue 1, Page 87-94, March 2026.
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger, Hannah F. Todd, Jonathan M. Yarimi, Timothy E. Lotze, Nikita M. Shukla, Kristen S. Fisher, Alexander J. Sandweiss   +6 more
wiley   +1 more source

Successful use of Remcyte®-based continuous hemodiafiltration in a case of refractory CRS and ICANS complicated by tumor lysis syndrome-associated AKI. [PDF]

CEN Case Rep
Yomogida D, Hasegawa S, Mizuta S, Horikawa S, Koshida Y.   +4 more
europepmc   +1 more source

Taming the Cytokine Storm: Therapeutic Strategies for Post‐Acute Sequelae of SARS‐CoV‐2 Infection

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aim Post‐acute sequelae of SARS‐CoV‐2 infection (PASC), commonly referred to as long COVID, has emerged as a significant global health concern, marked by persistent symptoms and chronic inflammation following recovery from acute COVID‐19.
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy. [PDF]

Front Immunol
Zhang J, Shi W, Yang J, Qian J, Su M, An K, Wang T, Jia R, Fei C, Tang Y, Li B.   +10 more
europepmc   +1 more source

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis. [PDF]

Rheumatology (Oxford)
Goldman NR, Nihtyanova SI, Beesley CF, Wells AU, Denton CP, Renzoni EA, Mageed R, Ong VH.   +7 more
europepmc   +1 more source

Isorhamnetin Alleviates Renal Fibrosis Induced by Renal Tubular Epithelial Cell Senescence Via Inhibition of the IL‐6/IL‐6R Signaling Pathway

iMetaMed, Volume 2, Issue 1, March 2026.
IL‐6 from RTECs upregulates TGF‐β in macrophages, promoting fibroblast transdifferentiation. Isorhamnetin inhibits this effect. ABSTRACT Chronic kidney disease (CKD) is a major global health issue. Kidney fibrosis is a key mechanism leading to end‐stage renal disease.
Weifei Liang, Xiangqiu Chen, Tao Wu, Xichun Zheng, Shaohua Zeng, Qingchun Zhou, Wen Ma, Hao Lin, Donglin Sun   +8 more
wiley   +1 more source

Severe Cytokine Release Syndrome After CAR T Cell Therapy in a Pediatric Patient With Relapsed ALL. [PDF]

Case Rep Oncol Med
Alotaibi A, Alajmi N, Alnuhait M.
europepmc   +1 more source